| INTRODUCTION
Cancer is a major threat to public health nowadays. Breast cancer, colorectal cancer, hepatocarcinoma and head and neck squamous cell carcinoma (HNSCC) rank among the most frequent cancers worldwide. The mechanisms underlying cancer development, however, are far from being fully understood. 1 Dysregulation of fibroblast growth factor receptor (FGFR)-dependent signaling has been observed in various tumors and is considered as an oncogenic signaling pathway. Several mechanisms are responsible for aberrant regulation of FGFR signaling, including altered expression, mutation, chromosomal rearrangement, and aberrant FGFR splicing. There is compelling evidence that dysregulated FGFR4 is also involved in the pathogenesis of many cancer types (Table 1) .
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| STRUCTURE OF FGFR4
All FGFR contain an extracellular domain, a transmembrane domain, and a cytoplasmic domain ( Figure 1A ). 19 The extracellular domain contains the leader peptide and 3 immunoglobulin domains (D1-3). After Alternative splicing of FGFR is a significant determinant of binding specificity, which is actually regulated in a tissue-specific manner.
Alternative splicing leads to 2 isoforms of FGFR: IIIb and IIIc, which have distinct ligand binding specificity. FGFR IIIb isoform is mainly expressed in epithelial tissues, whereas the IIIc isoform is mainly expressed in mesenchymal tissues. The isoforms expressed in epithelial tissues usually prefer to interact with the ligands expressed in mesenchymal tissues. In contrast, the isoforms expressed in mesenchymal tissues usually interact with the ligands expressed in epithelial tissues (Figure 2) . 24, 25 In addition, binding specificity is also Further, FGF19 is primarily expressed in the ileum and circulates to the liver to exert its liver-specific functions. Liver is also the only tissue where KLB and FGFR4 are highly expressed in human and mouse. 16, 26 This suggests that tissue-specific expression also regulates the specific binding of FGF19 to FGFR4.
| PHYSIOLOGICAL FUNCTION OF FGFR4
In general, FGFR4 is highly expressed in embryonic tissues and is involved in embryonic development, angiogenesis, and tissue differentiation. 27 In adult tissues, the expression of FGFR4 is limited in the actively growing tissues. The physiological effects of FGFR4 in adults include regulating bile acid production, metabolism, muscle differentiation, and tissue repair.
| Regulation of bile acid production
Bile acid is synthesized in the liver and is stored in the gallbladder.
Bile acid is secreted into the intestine, contributing to the absorption of nutrients in the intestine. FGF19 is the target gene of farnesoid X receptor. Postprandial intestinal bile acid is capable of activating farnesoid X receptor in the intestinal epithelium, resulting in expression and secretion of FGF19. 28 In turn, FGF19 activates the hepatic FGFR4, and reduces bile acid synthesis by inhibiting cholesterol 7α-hydroxylase (CYP7A1) expression, the rate-limiting enzyme in bile acid synthesis. The regulatory role of FGFR4 in bile acid production was also observed in FGFR4 knockout mice. CYP7A1 mRNA and protein in the liver of FGFR4 knockout mice are significantly higher than that in wild-type mice. In addition, liver 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMG-CoA reductase), the rate-limiting enzyme in cholesterol biosynthesis, is also upregulated. Accordingly, 
| Regulation of metabolism
The role of FGF19 in metabolism was identified by studying the phenotype of FGF19 transgenic mice or FGF19-treated mice. FGF19 transgenic mice show a phenotype of losing weight, decreased blood glucose, triglyceride and insulin, and enhanced metabolic rate, glucose tolerance, and insulin sensitivity compared with wild-type mice. 30 
| Muscle differentiation and tissue repair
In chick embryos, myoblasts from skeletal muscle masses have a high level of FGFR4 expression. Inhibition of FGFR4 impairs differentiation of muscle progenitor and results in a loss of limb muscles, which is seen as altered expression of muscle cell markers, such as myogenic factor 5 (Myf5), myogenic differentiation factor (MyoD), and the embryonic myosin heavy chain (MHC). 33 In addition, a soluble dominant-negative FGFR4-containing adenovirus was used to infect mouse myoblasts, the differentiation of these cells was markedly retarded in 4-day culture, accompanied by interruption of extracellular signal-regulated kinases (Erk) 1/2 phosphorylation and aberrant expression of MHC, suggesting that muscle differentiation is suppressed when the FGFR4 signaling pathway is blocked. 34 In normal adults, FGFR4 is expressed in myofibroblast during tissue repair after injury. The MyoD-Tead2-Fgfr4 pathway has been reported to be involved in muscle regeneration. 
| Aberrant expression of FGFR4
Overexpression of FGFR4 has been detected in multiple types of human cancer, such as breast cancer, liver cancer, colon cancer, prostate cancer, rhabdomyosarcoma, and is associated with decreased survival time. 
| Single-nucleotide polymorphism
The most well-known SNP of FGFR4 is codon 388 in exon 9, where the first base mutates from G to A. This mutation causes the coded amino residue to be changed from glycine (Gly388) into arginine (Arg388) in the transmembrane domain.
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The incidence of Arg388 is associated with several prognostic parameters in cancer. A statistically significant association of FGFR4
Arg388 with the prognosis of multiple cancers was noted in a metaanalysis and pooled analysis. 6 Some other studies have come to similar results. For example, Arg388 allele carriers were found to have a significantly reduced disease-free survival time compared with Gly388 homozygous allele carriers. 2 Moreover, the FGFR4 Arg388 allele carriers with colon cancer had early lymph node metastasis and advanced tumor-node-metastasis (TNM) stage, an indicator of poor cancer prognosis. 2 Another study focusing on HNSCC showed that only the HNSCC patients with the FGFR4 Arg388 allele died in the follow-up period, and showed a trend to a reduced overall survival. 7 Accordingly, in a study specifically focusing on the association between the FGFR4 Arg388 allele with oral squamous cell carcinoma (OSCC) development, it was shown that, compared with OSCC patients carrying the Gly/Gly genotype, the patients carrying the FGFR4 Arg/Arg or Arg/Gly genotype had advanced nodal stage (pathologic N2 + N3). Further, FGFR4 Arg388 allele and mutations in TP53 were associated with shorter survival time. These 2 parameters influenced the survival of OSCC patients synergistically. 8 The effects of FGFR4 388 variants on cancer progression were investigated in the MDA-MB-231 human breast cancer cell models. 9 It was found that expression of FGFR4 Gly388 allele suppressed cancer cell invasiveness and motility. This was probably mediated by regulating the expression of genes involved in Although the underlying mechanism is not fully clear yet, some studies indicate that Arg388 SNP prolongs FGFR4 half-life and increases its stability. 11 In other studies, the Arg388 variant recruiting signal transducer and activator of transcription 3 (STAT3) to the inner cell membrane has been suggested to be one of the molecular mechanisms. 12 The FGFR4 Arg388-variant changes transmembrane spanning segment, and also exposes the membrane-proximal The effects of the Y367C mutation on FGFR4 signaling are based on its promotion impact in FGFR4 dimerization. Adjacent cysteine residues facilitate the formation of disulphide bond connecting protein chains, so this mutation increases the incidence of FGFR4 dimerization on the cell surface, thereby leading to activation of receptor tyrosine kinase and ligand-independent activation of signaling pathways. 13 Several mutations in the FGFR4 kinase domain have been
reported in approximately 7%-8% of rhabdomyosarcoma, such as N535K and V550E mutations. 14 N535K and V550E mutations cluster in proximity to the FGFR4 tyrosine kinase domain ( Figure 4B ).
The N535K mutation disrupts FGFR4 R-group hydrogen bonds between N535 and residues H530 and I533, which inhibit receptor autophosphorylation. V550E mutation may alter the ATP binding cleft. In addition, the V550E mutation is considered an FGFR4 gatekeeper mutation, which increases the size of the gatekeeper residue and stabilizes the active state of FGFR4, thus leading to enhanced kinase activity. N535K and V550E mutations cause receptor autophosphorylation, then activate the STAT3 signal pathway, resulting in increased tumor cell proliferation and metastasis when expressed in murine rhabdomyosarcoma cell lines. 14 
| Aberrant regulation of FGFR4 ligands
Fibroblast growth factor 19 has been reported to promote the development of hepatocellular carcinoma (HCC). 15 Recombinant FGF19
can increase proliferation, and also inhibit apoptosis in HCC cell lines, while siRNA-mediated knockdown of FGF19 has the opposite effect. FGFR4 is the predominant FGF receptor expressed in liver that mediates the liver-specific function of FGF19. To study the role of FGFR4 in FGF19-induced hepatocyte proliferation, FGF19dCTD, a C-terminally truncated variant of FGF19 protein, was designed to activate FGFR4 but not FGFR 1c, 2c, and 3c. It was found that this specific activator of FGFR4 could induce hepatocyte proliferation. 16 This suggests that hepatic FGFR4 activation alone results in increased hepatocyte proliferation, which may be a prerequisite for neoplastic transformation. (Table 2 ).
| RNA interference
RNA interference is a phenomenon of degradation of homologous mRNA induced by double-stranded RNA (dsRNA). 38 were also observed in prostate cancer cells. 40 These data suggest that shRNA-mediated FGFR4 knockdown exerts its anti-tumor function partly by blocking the process of EMT.
| Small-molecule FGFR inhibitors
As the first generation of FGFR small-molecule inhibitors, mixed kinase inhibitors have a remarkably broad substrate specificity. These inhibitors showed even better effects on anti-VEGF receptor 
| Monoclonal antibody
The 
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